Tarlox-TKI

Tarlox-TKI, the active metabolite of Tarloxotinib, is an irreversible pan-ErbB TKI (Tarlox-TKI).

Product information

CAS Number: 2135696-72-7

Molecular Weight: 461.74

Formula: C19H18BrClN6O

Chemical Name: (2E)-N-{4-[(3-bromo-4-chlorophenyl)amino]pyrido[3, 4-d]pyrimidin-6-yl}-4-(dimethylamino)but-2-enamide

Smiles: CN(C)C/C=C/C(=O)NC1=CC2=C(NC3=CC(Br)=C(Cl)C=C3)N=CN=C2C=N1

InChiKey: QBACGOWRJDBXSG-ONEGZZNKSA-N

InChi: InChI=1S/C19H18BrClN6O/c1-27(2)7-3-4-18(28)26-17-9-13-16(10-22-17)23-11-24-19(13)25-12-5-6-15(21)14(20)8-12/h3-6,8-11H,7H2,1-2H3,(H,22,26,28)(H,23,24,25)/b4-3+

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 100 mg/mL (216.57 mM)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Epidermal Growth Factor Receptor (EGFR, HER1) is an attractive therapeutic target for many cancer types. Tarlox-TKI is a dose-potent EGFR inhibitor.

References:

1. Victoria Jackson-Patel, et al. Hypoxia tumour targeting with Tarloxotinib to improve clinical outcomes for patients with EGFR-dependent malignancies.

Products are for research use only. Not for human use.